Joselito Cabaccan, MD
Endocrinology, Diabetes & Metabolism · San Jose, CANPI 1801813720
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,145,773 of the $1,422,625 with a category attached, or 80.5%. 60 manufacturers reported payments, led by Lilly USA, LLC at 39.8% of the total. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4,063 payments — averaging $350.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$566K
- Novo Nordisk$314K
- Bayer$161K
- AstraZeneca$64K
- Boehringer Ingelheim$58K
- Sanofi-aventis U.S. LLC$53K
- plus $206K from 54 others
Across 99 payments — averaging $586.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$41K
- Novo Nordisk AS$17K
What the payments were for
- Consulting fees$38,9903%
- Speaking & faculty fees$1,145,77381%
- Travel & lodging$166,29112%
- Food & beverage$70,9665%
- Education$5870%
- Gifts$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$219,572
- MOUNJARO$175,727
- Kerendia$158,389
- RYBELSUS$143,632
- JARDIANCE$143,200
- Ozempic$135,013
- FARXIGA$61,178
- Korlym$38,508
- AFREZZA$25,227
- Repatha$23,787
- Yorvipath$22,070
- TZIELD$21,736
- Tresiba$19,774
- SOLIQUA 100/33$17,425
- TOUJEO$15,366
- STEGLATRO$14,664
- INVOKANA$14,325
- DEXCOM G7 GSS (161)$12,103
- PRALUENT$9,749
- DEXCOM G6 TRANSMITTER$6,406
How this compares
$1,422,625 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,000 | $1,616,758 |
| JardianceEmpagliflozin | 885 | $1,108,758 |
| TrulicityDulaglutide | 654 | $948,751 |
| MounjaroTirzepatide | 507 | $701,640 |
| KorlymMifepristone | 12 | $465,403 |
| FarxigaDapagliflozin Propanediol | 371 | $413,617 |
| AfrezzaInsulin Regular, Human | 109 | $392,762 |
| RybelsusSemaglutide | 209 | $372,971 |
| KerendiaFinerenone | 259 | $303,545 |
| Humalog Kwikpen U-200Insulin Lispro | 64 | $155,424 |
| Repatha SureclickEvolocumab | 161 | $147,085 |
| TymlosAbaloparatide | 47 | $129,318 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 101 | $112,616 |
| TradjentaLinagliptin | 116 | $110,913 |
| InvokanaCanagliflozin | 79 | $107,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $314,101 | $1,989,7291,209 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Forteo | $566,134 | $1,751,5551,182 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $58,389 | $1,393,3321,151 claims |
| Corcept TherapeuticsKorlym | $40,252 | $465,40312 claims |
| AstraZenecaFarxiga | $63,747 | $413,617371 claims |
| Mannkind CorporationAfrezza | $28,017 | $392,762109 claims |
| BayerKerendia | $161,012 | $303,545259 claims |
| AmgenProlia, Evenity (2 Syringes) | $35,724 | $131,78767 claims |
| Radius Health, Inc.Tymlos | $1,178 | $129,31847 claims |
| Johnson & JohnsonInvokana | $15,266 | $107,69179 claims |
| MerckJanuvia | $15,667 | $85,26077 claims |
| AbbVieSynthroid | $996 | $33,265312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in San Jose
- Archana BindraSan Jose$70K
- Juan FriasSan Diego$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.